{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T03:05:31Z","timestamp":1768273531637,"version":"3.49.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T00:00:00Z","timestamp":1606694400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T00:00:00Z","timestamp":1606694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>ZD55-IL-24 is similar but superior to the oncolytic adenovirus ONYX-015, yet the exact mechanism underlying the observed therapeutic effect is still not well understood. Here we sought to elucidate the underlying antitumor mechanism of ZD55-IL-24 in both immunocompetent and immunocompromised mouse model. We find that ZD55-IL-24 eradicates established melanoma in B16-bearing immunocompetent mouse model not through the classic direct killing pathway, but mainly through the indirect pathway of inducing systemic antitumor immunity. Inconsistent with the current prevailing view, our further results suggest that ZD55-IL-24 can induce antitumor immunity in B16-bearing immunocompetent mouse model in fact not due to its ability to lyse tumor cells and release the essential elements, such as tumor-associated antigens (TAAs), but due to its ability to put a \u201cnonself\u201d label in tumor cells and then turn the tumor cells from the \u201cself\u201d state into the \u201cnonself\u201d state without tumor cell death. The observed anti-melanoma efficacy of ZD55-IL-24 in B16-bearing immunocompetent mouse model was practically caused only by the viral vector. In addition, we also notice that ZD55-IL-24 can inhibit tumor growth in B16-bearing immunocompetent mouse model through inhibiting angiogenesis, despite it plays only a minor role. In contrast to B16-bearing immunocompetent mouse model, ZD55-IL-24 eliminates established melanoma in A375-bearing immunocompromised mouse model mainly through the classic direct killing pathway, but not through the antitumor immunity pathway and anti-angiogenesis pathway. These findings let us know ZD55-IL-24 more comprehensive and profound, and provide a sounder theoretical foundation for its future modification and drug development.<\/jats:p>","DOI":"10.1038\/s41419-020-03223-0","type":"journal-article","created":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T18:03:12Z","timestamp":1606759392000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["The armed oncolytic adenovirus ZD55-IL-24 eradicates melanoma by turning the tumor cells from the self-state into the nonself-state besides direct killing"],"prefix":"10.1038","volume":"11","author":[{"given":"Hai-Jun","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai-Lang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Ming","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Li","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huai-Yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Fa","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai-Min","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan-Ying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Qing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Song","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Ting","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kang-Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin-Yuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,30]]},"reference":[{"key":"3223_CR1","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/nbt.2287","volume":"30","author":"SJ Russell","year":"2012","unstructured":"Russell, S. J., Peng, K.-W. & Bell, J. C. Oncolytic virotherapy. Nat. Biotechnol. 30, 658\u2013670 (2012).","journal-title":"Nat. Biotechnol."},{"key":"3223_CR2","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1089\/hum.2005.16.845","volume":"16","author":"L Zhao","year":"2005","unstructured":"Zhao, L. et al. Potent antitumor activity of oncolytic adenovirus expressing mda-7\/IL-24 for colorectal cancer. Hum. Gene Ther. 16, 845\u2013858 (2005).","journal-title":"Hum. Gene Ther."},{"key":"3223_CR3","volume-title":"Recent Advances in Cancer Research and Therapy.","author":"X Liu","year":"2013","unstructured":"Liu, X., Pestka, S. & Shi, Y. Recent Advances in Cancer Research and Therapy. (Tsinghua University Press, Beijing, 2013)."},{"key":"3223_CR4","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/sj.cr.7290191","volume":"13","author":"Z Zhang","year":"2003","unstructured":"Zhang, Z. et al. An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy. Cell Res. 13, 481\u2013489 (2003).","journal-title":"Cell Res."},{"key":"3223_CR5","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nrd4663","volume":"14","author":"HL Kaufman","year":"2015","unstructured":"Kaufman, H. L., Kohlhapp, F. J. & Zloza, A. Oncolytic viruses: a new class of immunotherapy drugs. Nat. Rev. Drug Discov. 14, 642\u2013662 (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3223_CR6","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1038\/nbt887","volume":"21","author":"Y Wang","year":"2003","unstructured":"Wang, Y. et al. E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models. Nat. Biotechnol. 21, 1328\u20131335 (2003).","journal-title":"Nat. Biotechnol."},{"key":"3223_CR7","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/sj.leu.2405034","volume":"22","author":"W Qian","year":"2008","unstructured":"Qian, W. et al. Enhanced antitumor activity by a selective conditionally replicating adenovirus combining with MDA-7\/interleukin-24 for B-lymphoblastic leukemia via induction of apoptosis. Leukemia 22, 361\u2013369 (2008).","journal-title":"Leukemia"},{"key":"3223_CR8","doi-asserted-by":"publisher","first-page":"60491","DOI":"10.18632\/oncotarget.11134","volume":"7","author":"S Yuan","year":"2016","unstructured":"Yuan, S. et al. An oncolytic adenovirus that expresses the HAb18 and interleukin 24 genes exhibits enhanced antitumor activity in hepatocellular carcinoma cells. Oncotarget 7, 60491\u201360502 (2016).","journal-title":"Oncotarget"},{"key":"3223_CR9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3109\/02841860903246557","volume":"49","author":"S Zhong","year":"2009","unstructured":"Zhong, S. et al. An armed oncolytic adenovirus ZD55-IL-24 combined with ADM or DDP demonstrated enhanced antitumor effect in lung cancer. Acta Oncol. 49, 91\u201399 (2009).","journal-title":"Acta Oncol."},{"key":"3223_CR10","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.addr.2011.12.011","volume":"64","author":"J-W Choi","year":"2012","unstructured":"Choi, J.-W., Lee, J.-S., Kim, S. W. & Yun, C.-O. Evolution of oncolytic adenovirus for cancer treatment. Adv. Drug Deliv. Rev. 64, 720\u2013729 (2012).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"3223_CR11","volume-title":"Adenoviral Vectors for Gene Therapy.","author":"DT Curiel","year":"2016","unstructured":"Curiel, D. T. Adenoviral Vectors for Gene Therapy. 2nd edn (Elsevier Academic Press, London, 2016).","edition":"2nd edn"},{"key":"3223_CR12","doi-asserted-by":"publisher","first-page":"11548","DOI":"10.1021\/acsnano.6b06182","volume":"10","author":"J Chen","year":"2016","unstructured":"Chen, J. et al. Oncolytic adenovirus complexes coated with lipids and calcium phosphate for cancer gene therapy. Acs Nano 10, 11548\u201311560 (2016).","journal-title":"Acs Nano"},{"key":"3223_CR13","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/sj.cgt.7700969","volume":"13","author":"L Zhao","year":"2006","unstructured":"Zhao, L. et al. The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer. Cancer Gene Ther. 13, 1011\u20131022 (2006).","journal-title":"Cancer Gene Ther."},{"key":"3223_CR14","doi-asserted-by":"publisher","first-page":"226ra232","DOI":"10.1126\/scitranslmed.3008095","volume":"6","author":"D Zamarin","year":"2014","unstructured":"Zamarin, D. et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci. Transl. Med. 6, 226ra232 (2014).","journal-title":"Sci. Transl. Med."},{"key":"3223_CR15","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aao1641","volume":"10","author":"M-C Bourgeois-Daigneault","year":"2018","unstructured":"Bourgeois-Daigneault, M.-C. et al. Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy. Sci. Transl. Med 10, eaao1641 (2018).","journal-title":"Sci. Transl. Med"},{"key":"3223_CR16","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41573-019-0029-0","volume":"18","author":"K Harrington","year":"2019","unstructured":"Harrington, K., Freeman, D. J., Kelly, B., Harper, J. & Soria, J.-C. Optimizing oncolytic virotherapy in cancer treatment. Nat. Rev. Drug Discov. 18, 689\u2013706 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3223_CR17","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/nprot.2010.43","volume":"5","author":"L Young","year":"2010","unstructured":"Young, L., Sung, J., Stacey, G. & Masters, J. R. Detection of mycoplasma in cell cultures. Nat. Protoc. 5, 929\u2013934 (2010).","journal-title":"Nat. Protoc."},{"key":"3223_CR18","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1200\/JCO.2014.58.0209","volume":"33","author":"S Fang","year":"2015","unstructured":"Fang, S. et al. C-reactive protein as a marker of melanoma progression. J. Clin. Oncol. 33, 1389\u20131396 (2015).","journal-title":"J. Clin. Oncol."},{"key":"3223_CR19","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1038\/nm.4200","volume":"22","author":"KD Moynihan","year":"2016","unstructured":"Moynihan, K. D. et al. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat. Med. 22, 1402\u20131410 (2016).","journal-title":"Nat. Med."},{"key":"3223_CR20","unstructured":"Murphy, K. Janeway\u2019s Immunobiology 8 edn (Garland Science, London, 2012)."},{"key":"3223_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","volume":"20","author":"SK Wculek","year":"2020","unstructured":"Wculek, S. K. et al. Dendritic cells in cancer immunology and immunotherapy. Nat. Rev. Immunol. 20, 7\u201324 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"3223_CR22","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1089\/hum.2017.033","volume":"28","author":"Z Liu","year":"2017","unstructured":"Liu, Z. et al. An oncolytic adenovirus encoding decorin and GM-CSF inhibits tumor growth in a colorectal tumor model by targeting pro-tumorigenic signals and via immune-activation. Hum. Gene Ther. 28, 667\u2013680 (2017).","journal-title":"Hum. Gene Ther."},{"key":"3223_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0097407","volume":"9","author":"H Jiang","year":"2014","unstructured":"Jiang, H. et al. Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model. PLoS ONE 9, e97407 (2014).","journal-title":"PLoS ONE"},{"key":"3223_CR24","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1158\/2326-6066.CIR-14-0015","volume":"2","author":"EA Chiocca","year":"2014","unstructured":"Chiocca, E. A. & Rabkin, S. D. Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol. Res. 2, 295\u2013300 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"3223_CR25","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1182\/blood.V90.4.1611","volume":"90","author":"PP Lee","year":"1997","unstructured":"Lee, P. P. et al. T helper 2-dominant antilymphoma immune response is associated with fatal outcome. Blood 90, 1611\u20131617 (1997).","journal-title":"Blood"},{"key":"3223_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coi.2016.04.005","volume":"41","author":"M Bassani-Sternberg","year":"2016","unstructured":"Bassani-Sternberg, M. & Coukos, G. Mass spectrometry-based antigen discovery for cancer immunotherapy. Curr. Opin. Immunol. 41, 9\u201317 (2016).","journal-title":"Curr. Opin. Immunol."},{"key":"3223_CR27","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/77283","volume":"18","author":"R Alemany","year":"2000","unstructured":"Alemany, R., Balagu\u00e9, C. & Curiel, D. T. Replicative adenoviruses for cancer therapy. Nat. Biotechnol. 18, 723\u2013727 (2000).","journal-title":"Nat. Biotechnol."},{"key":"3223_CR28","doi-asserted-by":"crossref","unstructured":"Flint, J., Racaniello, V. R., Rall, G. F., Skalka, A. M. & Enquist, L. W. Principles of Virology (ASM Press, Washington, 2015).","DOI":"10.1128\/9781555819521"},{"key":"3223_CR29","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/nrc1750","volume":"5","author":"KA Parato","year":"2005","unstructured":"Parato, K. A., Senger, D., Forsyth, P. A. J. & Bell, J. C. Recent progress in the battle between oncolytic viruses and tumours. Nat. Rev. Cancer 5, 965\u2013976 (2005).","journal-title":"Nat. Rev. Cancer"},{"key":"3223_CR30","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1084\/jem.20042004","volume":"200","author":"SR Riddell","year":"2004","unstructured":"Riddell, S. R. Finding a place for tumor-specific T cells in targeted cancer therapy. J. Exp. Med. 200, 1533\u20131537 (2004).","journal-title":"J. Exp. Med."},{"key":"3223_CR31","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.semcancer.2007.06.006","volume":"17","author":"RH McMahan","year":"2007","unstructured":"McMahan, R. H. & Slansky, J. E. Mobilizing the low-avidity T cell repertoire to kill tumors. Semin. Cancer Biol. 17, 317\u2013329 (2007).","journal-title":"Semin. Cancer Biol."},{"key":"3223_CR32","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/S1471-4906(01)02110-X","volume":"23","author":"M Ferrarini","year":"2002","unstructured":"Ferrarini, M., Ferrero, E., Dagna, L., Poggi, A. & Zocchi, M. R. Human gammadelta T cells: a nonredundant system in the immune-surveillance against cancer. Trends Immunol. 23, 14\u201318 (2002).","journal-title":"Trends Immunol."},{"key":"3223_CR33","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.semcancer.2007.07.001","volume":"17","author":"B Seliger","year":"2007","unstructured":"Seliger, B. & Schlaf, G. Structure, expression and function of HLA-G in renal cell carcinoma. Semin. Cancer Biol. 17, 444\u2013450 (2007).","journal-title":"Semin. Cancer Biol."},{"key":"3223_CR34","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/ijc.29375","volume":"138","author":"F Garrido","year":"2016","unstructured":"Garrido, F., Romero, I., Aptsiauri, N. & GarciaLora, A. M. Generation of MHC class I diversity in primary tumors and selection of the malignant phenotype. Int. J. Cancer 138, 271\u2013280 (2016).","journal-title":"Int. J. Cancer"},{"key":"3223_CR35","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/mt.2010.297","volume":"19","author":"SA Gujar","year":"2011","unstructured":"Gujar, S. A., Pan, D., Marcato, P., Garant, K. A. & Lee, P. W. Oncolytic virus-initiated protective immunity against prostate cancer. Mol. Ther. 19, 797\u2013804 (2011).","journal-title":"Mol. Ther."},{"key":"3223_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15229-5","volume":"11","author":"G Wang","year":"2020","unstructured":"Wang, G. et al. An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses. Nat. Commun. 11, 1395 (2020).","journal-title":"Nat. Commun."},{"key":"3223_CR37","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nri3174","volume":"12","author":"E Vivier","year":"2012","unstructured":"Vivier, E., Ugolini, S., Blaise, D., Chabannon, C. & Brossay, L. Targeting natural killer cells and natural killer T cells in cancer. Nat. Rev. Immunol. 12, 239\u2013252 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"3223_CR38","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nm.f.1774","volume":"14","author":"V Appay","year":"2008","unstructured":"Appay, V., Douek, D. C. & Price, D. A. CD8+ T cell efficacy in vaccination and disease. Nat. Med. 14, 623\u2013628 (2008).","journal-title":"Nat. Med."},{"key":"3223_CR39","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","volume":"14","author":"A Mantovani","year":"2017","unstructured":"Mantovani, A., Marchesi, F., Malesci, A., Laghi, L. & Allavena, P. Tumour-associated macrophages as treatment targets in oncology. Nat. Rev. Clin. Oncol. 14, 399\u2013416 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"3223_CR40","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41577-018-0044-0","volume":"18","author":"J Borst","year":"2018","unstructured":"Borst, J., Ahrends, T., B\u0105ba\u0142a, N., Melief, C. J. M. & Kastenm\u00fcller, W. CD4+ T cell help in cancer immunology and immunotherapy. Nat. Rev. Immunol. 18, 635\u2013647 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"3223_CR41","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ctrv.2018.10.012","volume":"71","author":"CL-L Chiang","year":"2018","unstructured":"Chiang, C. L.-L. & Kandalaft, L. E. In vivo cancer vaccination: which dendritic cells to target and how? Cancer Treat. Rev. 71, 88\u2013101 (2018).","journal-title":"Cancer Treat. Rev."},{"key":"3223_CR42","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jaut.2018.08.007","volume":"95","author":"P Kumara","year":"2018","unstructured":"Kumara, P., Bhattacharyaa, P. & Prabhakar, B. S. A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity. J. Autoimmun. 95, 77\u201399 (2018).","journal-title":"J. Autoimmun."},{"key":"3223_CR43","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nri2580","volume":"9","author":"Y Rochman","year":"2009","unstructured":"Rochman, Y., Spolski, R. & Leonard, W. J. New insights into the regulation of T cells by \u03b3c family cytokines. Nat. Rev. Immunol. 9, 480\u2013490 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"3223_CR44","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S1359-6101(03)00049-2","volume":"14","author":"E Schutyser","year":"2003","unstructured":"Schutyser, E., Struyf, S. & Van Damme, J. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev. 14, 409\u2013426 (2003).","journal-title":"Cytokine Growth Factor Rev."},{"key":"3223_CR45","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.cytogfr.2010.08.004","volume":"21","author":"R Dash","year":"2010","unstructured":"Dash, R. et al. Mda-7\/IL-24: a unique member of the IL-10 gene family promoting cancer-targeted toxicity. Cytokine Growth Factor Rev. 21, 381\u2013391 (2010).","journal-title":"Cytokine Growth Factor Rev."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-03223-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-03223-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-03223-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T15:57:30Z","timestamp":1670255850000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-03223-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,30]]},"references-count":45,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11]]}},"alternative-id":["3223"],"URL":"https:\/\/doi.org\/10.1038\/s41419-020-03223-0","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,30]]},"assertion":[{"value":"5 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"X.-Y.L., J.-F.G., and L.-Y.S. are inventors on a patent for the construction and application of ZD55-IL-24 (US Patent and Trademark Office, 20090117643A1). The other authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"1022"}}